OWC Pharmaceutical Research Stock Price - OWCP

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$65.99
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$30.00
SMALL CAP PRO
Monthly Subscription
for only
$43.59
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN Company Description
Owc Pharmaceutical Research Corp. (QB) OWCP Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded DELAYED
  +0.245 +36.57% 0.915 0.94 0.69 0.707 0.67 16:41:22
Bid Price Ask Price Spread Spread % News
0.91 0.949 0.039 4.11% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
2,559 6,767,783 $ 0.8334 $ 5.64M 2.57M - - -
Last Trade Time Type Quantity Stock Price Currency
15:59:56 100 $0.92 USD

Owc Pharmaceutical Research Corp. (QB) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 129.42M 141.45M $ -1.65M - -78.20 86.52M
Short Interest Short % of Out Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
1.77M 1.25% $ - 0.00% - -

more financials information »

Owc Pharmaceutical Research Corp. (QB) News


Historical OWCP Price Data

Period † Open High Low VWAP Min Vol Max Vol Avg. Daily Vol [m] Change %
1 Week0.6250.940.58390.0000980k7M1M0.2946.40%
1 Month0.5450.940.480.0000980k7M2M0.3767.89%
3 Months0.11950.950.0870.0000306k15M3M0.7955665.69%
6 Months0.0250.950.0030.0000065M6M0.893,560.00%
1 Year0.07450.950.0030.0000065M3M0.84051,128.19%
3 Years0.04010.950.0030.0000065M976k0.87492,181.80%
5 Years0.00130.950.00080.0000065M828k0.913770,284.62%

Owc Pharmaceutical Research Corp. (QB) Description

OWC Pharmaceutical Research Corp. engaged in the business, through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd. ("OWC"), of conducting medical research and clinical trials, in full compliance with all international regulatory protocols, for the development and improvement of strains of non-psychoactive medical cannabis specifically designed for the treatment of several illnesses/medical conditions. Under the direction of Dr. Yehuda Baruch, our Director of Research and Regulatory Affairs, the Company has identified and prioritized several conditions that it believes will respond positively to cannabis-based therapies using specific dosages administered through soluble pills taken orally. Our initial focus will include PTSD, psoriasis, multiple myeloma and topical treatment of burns. Our business plan includes entering into collaborative ventures with major medical centers and highly regarded researchers in Israel and potentially other countries with the goal of developing novel therapeutic methods for the treatment of serious medical conditions with cannabis-based therapies. Through our collaboration agreements, we are conducting pre-clinical investigations and randomized, placebo-controlled trials of cannabis-based compounds and develop unique, condition-specific products.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.